Brief: Egetis Receives Positive EMA Opinion For Orphan Designation Of Emcitate
24/03/2022 07:06
March 24 (Reuters) - Egetis Therapeutics AB (publ)
EGTX.ST :
* EGETIS RECEIVES POSITIVE EMA OPINION FOR ORPHAN
DESIGNATION OF
EMCITATE FOR TREATMENT OF RESISTANCE TO THYROID HORMONE TYPE
BETA (RTH-Β)
Source text for Eikon: ID:nMFN56ftfq
Further company coverage: EGTX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))